Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives

Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease worldwide, reaching one of the highest prevalences in patients with type 2 diabetes mellitus (T2DM). For now, no specific pharmacologic therapies are approved to prevent or treat NAFLD. Glucagon-like peptide-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazac, Georgiana-Diana, Lăcătușu, Cristina-Mihaela, Ștefănescu, Gabriela, Mihai, Cătălina, Grigorescu, Elena-Daniela, Onofriescu, Alina, Mihai, Bogdan-Mircea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221116/
https://www.ncbi.nlm.nih.gov/pubmed/37233622
http://dx.doi.org/10.3390/metabo13050581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221116/
https://www.ncbi.nlm.nih.gov/pubmed/37233622
http://dx.doi.org/10.3390/metabo13050581

Ejemplares similares